New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 5, 2003, Pages 411-416

  El Demerdash, Ebtehal ^a   Ali, Azza A ^b   Sayed Ahmed, Mohamed M ^c   Osman, Abdel Moneim M ^c  

^a Ain Shams University   (Egypt)

^b Al Azhar University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Cardiotoxicity; Doxorubicin; Pharmacokinetics; Probucol

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; CHOLESTEROL; CREATINE KINASE; DOXORUBICIN; LOW DENSITY LIPOPROTEIN; PROBUCOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; ENZYME BLOOD LEVEL; HEART; HEART PROTECTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALGORITHMS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHOLESTEROL; CREATINE KINASE; DOXORUBICIN; HALF-LIFE; HEART DISEASES; LIPID METABOLISM; LIPIDS; MALE; MYOCARDIUM; NUCLEOTIDES; PROBUCOL; RATS;

EID: 0242329655     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0676-y     Document Type: Article

References (35)

1. Behnia K, Boroujerdi M (1999) Inhibition of aldo-keto reductase by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J Pharm Pharmacol 51:1275
2. Bridges AB, Scott NA, Blech JJF (1991) Probucol, a superoxide free radical scavenger in-vitro. Atherosclerosis 89:263
3. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19:476
4. Dawson DM, Eppenberger HM, Kaplan NO (1965) Creatine kinase: evidence for a dimeric structure. Biochem Biophys Res Commun 21:346
5. Eksborg S, Stendahl U, Lonroth U (1986) Comparative pharmacokinetic study of adriamycin and 4′-epiadriamycin after their simultaneous intravenous administration. Eur J Clin Pharmacol 30:629
6. Formelli F, Pollini C, Carazza AM, DiMarco A, Mariani A (1981) Fluorescence assays and pharmacokinetic studies of 4′-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Cancer Chemother Pharmacol 5:139
7. Geetha A, Sankar R, Marar T, Devi CSS (1990) α-tocopherol reduces doxorubicin-induced toxicity in rats: histological and biochemical evidences. Indian J Physiol Pharmacol 34:94
8. Li T, Singal PK (2000) Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102:2105
9. Lliskovic N, Singal PK (1997) Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150:727
10. Mason RP (1993) Membrane interaction of calcium channel antagonists modulated by cholesterol: implication for drug activity. Biochem Pharmacol 45:2173
11. 2. Cancer Res 61:4024
12. Modi KS, Morrissey J, Shah SV, Schreiner GF, Klahr S (1990) Effects of probucol on renal function in rats with bilateral ureteral obstruction. Kidney Int 38:843
13. Muhammed H, Ramasarma T, Kurup CKR (1983) Inhibition of mitochondrial oxidative phosphorylation by adriamycin. Biochim Biophys Acta 722:43
14. Myers CE (1992) Anthracyclines. In: Pinedo HM, Longo DL, Chabner BA (eds) Cancer chemotherapy and biological modifiers (annual 13). Elsevier, New York, p 45
15. Neri B, Cini-Neri G, Bartalucci S, Bandinelli M (1986) Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vivo. Anticancer Res 6:659
16. Norlen P, Kitano M, Lindstrom E, Hakanson R (2000) Anaesthetic agents inhibit gastrin-stimulated but not basal histamine release from rat stomach ECL cells. Br J Pharmacol 130:725
17. Powis G (1991) Toxicity of free radical forming anticancer drugs. In: Powis G, Hacker MP (eds) The toxicity of anticancer drugs. Pergamon, New York, p 106
18. Preus M, Bhargava AS, Khater AER, Gunzel P (1988) Diagnostic value of serum creatine kinase and lactate dehydrogenase isoenzyme determinations for monitoring early cardiac damage in rats. Toxicol Lett 42:225
19. Ramanathan-Girish S, Boroujerdi M (2001) Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single-and multiple-dosing in rats. J Pharm Pharmacol 53:987
20. Rhaman M, Carmichael D, Harris M, Roh JK (1986) Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 46:2295
21. Richmond W (1973) Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 19:1350
22. Ritschel WA (1976) Handbook of basic pharmacokinetics. Drug Intelligence Publications, Hamilton, IL, p 210
23. Scheulen ME, Kappus H (1992) Anthracyclines as model compounds for cardiac toxicity. In: Dekant W, Neumann HG (eds) Tissue specific toxicity: biochemical mechanisms. Academic Press, New York, p 221
24. Seymour LW, Ulbrich K, Strohalm J, Kopecek J, Duncan R (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol 39:1125
25. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, Pourdjabbar A, Jasmin JF, Sarrazin JF, Liu P, Adam A, Butany J, Rouleau JL (2002) Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 105:2549
26. Sia YT, Parke TG, Liu P, Tsoporis JN, Adam A, Rouleau JL (2002) improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol 39:148
27. Siveski-Iliskovic N, Kaul N, Singal PK (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89:2829
28. Siveski-Iliskovic N, Hill M, Chow D, Singal PK (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor properties. Circulation 91:10
29. Smith IE (1985) Optimal schedule for anthracyclines. Eur J Cancer Clin Oncol 21:159
30. Sternberg SS, Philips FS, Cronin AP (1972) Renal tumors and other lesions in rats following a single intravenous injection of daunomycin. Cancer Res 32:1029
31. Vaidyanathan S, Boroujerdi M (2000) Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. Cancer Chemother Pharmacol 46:185
32. Vora J, Boroujerdi M (1996) Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisole-mediated reduction in anthracyclin cardiotoxicity. J Pharm Pharmacol 48:1264
33. Vora J, Khaw B, Narula J, Boroujerdi M (1996) Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J Pharm Pharmacol 48:940
34. Zimetbaum P, Eder H, Frishman W (1990) Probucol: pharmacology and clinical application. J Clin Pharmacol 30:3
35. Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R (1994) Antitumor activity of free and liposome-entrapped adriamycin, a lipophilic anthracycline antibiotic with noncross-resistance properties. Cancer Res 54:1479